1. Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz 1, Sherry X. Yan 2, Tony Wang 1, Clifford Chao 1, Tom K. Hei 1 1 New York Presbyterian Hospital / Columbia University Medical Center, 2 Columbia University, New York, NY Poster # 1139

2. Disclosures: None

3. – cancer patients are exposed to catecholamines under chronic stress conditions – promotes cellular proliferation, tumor invasion, angiogenesis, and resistance to chemotherapy-induced apoptosis – beta-blockers commonly used to treat hypertension and cardiac disease

4. PC9 lung cancer cells

5. No BBBB Total patients (n=101) 80%20% Age (avg)64 yo68 yo Males60% 71% Stage IIIA N2+ 75% 73% 78% 66% Histology Squamous Adeno Carcinoma NOS 26% 57% 16% 36% 52% 10%

6. NS

7. p=0.007 *

8. No BBBB OS 1yr68%82% (SS) OS 2yr53% 72% (NS)

9. – β-adrenergic pathway may regulate multiple processes that contribute to tumor progression and treatment response – propranolol radiosensitizes lung cancer cells to radiation in vitro –beta-blocker use was associated with a decreased distant metastases rate and improved overall survival at 1 year In LA- NSCLC pts treated with tri-modality therapy

10. – Need additional studies evaluating the benefits of beta-blocker use on radiation treatment response and lung cancer recurrence – Commonly targeted medical pathways may have significant pleomorphic effects on the efficacy of cancer therapies – e.g. NRG LU001 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC